Allergy Therapeutics plc (LON:AGY – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 7 ($0.09) and last traded at GBX 6.53 ($0.08), with a volume of 2477185 shares changing hands. The stock had previously closed at GBX 6.80 ($0.09).
Allergy Therapeutics Stock Performance
The firm has a fifty day moving average of GBX 5.61 and a 200-day moving average of GBX 5.09. The company has a quick ratio of 1.48, a current ratio of 1.40 and a debt-to-equity ratio of 37.22. The firm has a market cap of £311.24 million, a P/E ratio of -108.75, a PEG ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
- Five stocks we like better than Allergy Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- 3 Stocks Helping to Bring AI to Healthcare
- Overbought Stocks Explained: Should You Trade Them?
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
